Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Sort By:
Aug 14, 2020
Aug 14, 2020


Marietta, Ohio, August 14, 2020                                                                                                         ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due the results that AAGP® has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing. “In our in vitro model of rat...Read more
Jul 20, 2020
For anyone living with Type 1 diabetes, there is no doubt it is a challenging illness. Type 1 diabetes occurs at no fault of the patient, but unfortunately, there is no known cause or cure. ProtoKinetix researchers are actively exploring the potential for our anti-aging glycopeptide, AAGP®, to make better treatments possible. Continue reading to learn...Read more
Jul 14, 2020
When you are diagnosed with diabetes, you might initially feel overwhelmed and helpless. This chronic condition isn’t easy to live with all the time, since there are physical side effects of diabetes, as well as emotional and mental effects. Fortunately, there is active research being done to help uncover a cure, including studies conducted by...Read more
Jul 13, 2020
According to the Centers for Disease Control and Prevention (CDC), there were more than 30.3 million diagnosed cases of diabetes in the U.S. in 2015, and more than 100 million Americans are living with diabetes or prediabetes. While there is currently no cure, active research is being done, including studies by ProtoKinetix principal investigators to uncover...Read more
Marietta, Ohio, July 13, 2020                                                                                                              ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020. The amendments to the clinical trial protocol have been submitted by the University of Alberta to Health Canada for their review.  Upon approval from Health Canada and...Read more
Marietta, Ohio, July 7, 2020                                                                                                                ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.   Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product...Read more
Marietta, Ohio, April 6, 2020                                                                                                               ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of its AAGP® (PKX-001) molecule, announces preliminary results in efficacy and safety for use in treating Dry Eye Disease (DED). PKX-001 demonstrates a protective effect in...Read more
Marietta, Ohio, March 24, 2020 ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020. We have now completed the sterilization, quality assurance, labeling of the AAGP® (PKX-001) and are ready to ship the final product to the University of...Read more
Mar 19, 2020



ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease
Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule.  During recent testing conducted by EyeCRO of Oklahoma City, using a well-established animal model for dry eye disease (DED), it was observed that AAGP® may have a substantial effect on...Read more
Marietta, Ohio, Feb. 19, 2020 ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage and...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule